Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

OUTLOOK THERAPEUTICS INC (OTLK)

NASDAQ
Currency in USD
Disclaimer
8.170
-0.120(-1.45%)
Closed
After Hours
8.000-0.170(-2.081%)

OTLK Comments

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial OperationsJoel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account managementISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.“Outlook Therapeutics is thrilled to welcome Joel to our executive leadership team. We believe his background and expertise in commercialization and specialty biopharmaceutical distribution will be invaluable as we continue advancing our pre-launch commercial planning in anticipation of potential approval for ONS-5010 ophthalmic bevacizumab,” stated Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics.Mr. Prieve has nearly twenty years of experience in commercial operations, most recently in the Xcenda division of AmerisourceBergen as Vice President of Business Development and previously in the IPN Solutions division. Over the course of his career, he has amassed valuable leadership experience in sales management and national account management across oncology and specialty biopharmaceutical markets. His expertise in Group Purchasing Organization (GPO) contracting for retina/ophthalmology markets and his proven track record of successful partnerships for new product launches will be key for Outlook Therapeutics’ advancement of ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) towards potential commercialization.In his new role as SVP of Commercial Operations, Mr. Prieve will report to Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics, and oversee all aspects of distribution, third-party logistics, HUB services and field resources to deliver an industry-leading customer experience.Mr. Prieve added, “I am delighted to join Outlook Therapeutics at such an important stage of its development. I look forward to working with Jeff and the rest of the team on the potential commercial launch of ONS-5010.” Outlook Therapeutics expects to submit a Biologics License Application (BLA) for ONS-5010 ophthalmic bevacizumab with the U.S. Food and Drug Administration (FDA) during the first quarter of 2022. In anticipation of potential FDA marketing approval in late 2022 or early 2023, Outlook Therapeutics’ commercial launch planning includes manufacturing with drug substance manufacturer FUJIFILM Diosynth Biotechnologies and best-in-class drug product manufacturer Aji Biopharma Services, distribution, sales force planning, physician and payor advisory board outreach, key opinion leader support and payor community engagement.To bring ONS-5010 to market in a way that benefits all stakeholders – patients, clinicians and payors – Outlook Therapeutics is in collaborative discussions with payors and the retina community. Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and expects to submit them in the fourth quarter of 2022. Outlook Therapeutics continues to explore potential strategic commercialization partners, such as Syntone Biopharma JV in China. Outlook Therapeutics expects ONS-5010, if approved, to be a safe and cost-effective choice for patients, clinicians and payors worldwide for retinal indications.
ONS-5010. Hay incongruencias en fechas de aprobacion en las diferentes plataformas de consulta. Alguien puede aclarar (2021 o 2022?)
Outlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year
OTLK Price Targets:8,00 : Brookline Capital Markets, Following Clinical Business Update8,00/7,00/6,00 : BARCHART8,00/6,67/6,00 : YAHOO FINANCE (BUY) ; BARRONS (BUY) ; WEBULL (BUY) ; WSJ (BUY) ; STOCK NEWS (BUY) ; MARKET SCREENER (BUY) ; NASDAQ [STRONG BUY]8,00/6,00/6,00 : CNN BUSINESS (BUY) ; MARKET WATCH (BUY)7,00 ; ZACKS6,00 ; TIPRANKS (Moderate Buy) ; H C WAINWRIGHT ; MARKETBEAT [BUY]
As expected..... buying pressure began last friday and continues .... Institutions have taken positions and built a base. We are in a Uptrend, Last "6 days" of OTLK continuous in a Uptrend.
I closed yestrday my position on OTLK but very interested to join again, what are you targets?
This is going to 8 soon
Can you explain Why ? please
U need to do your research
 i did mine and want to know if my research is on right track.
Told you this was a garbage pump and dump stock
Dump or HOLD ??
Hold
flatline
Someone has information regarding long-term fundamentals, speculations are temporary, but fundamentals remain long-term.
there's no new news on why it should tank. it'll come back
There was no news why it went up 300% in days either. It will go down. PUMPED AND DUMPED
 it shot up quickly (I think) due largely inpart of the insider buying.  There's a call coming up which can either bring good news or bad news. I think folks who were on the bandwagon too their earnings already
I'm holding!
Is this going to keep tanking . Bought at 4 thinking it would keep rising?
they have an earnings call coming up... thnking it should come back
Well that was silly of you 🤣
What happened
what the ******happened
Pumped and now dumped!!
Any reason why you think its a pump and dump? (outside of the obvious fact people are going to cash out from a significant jump).  Just wondering
Target OTLK 4.0
Have another beer tard
 why
bought at 2.64 .. who is the tard
wow what is going on in after market
Hello do you think its a good idea to buy some now ?
Huge pump and dump scam here, sell fast!!!
It did gained way too much today, but there're reasons for it, such as huge insider buy before earnings report. It's not a scam, but I get where you're coming from, it's growing way too fast.
can sell now?
Hold . Big insider purchases
That is +44 percent in a day. Wow...
Insiders bought about 11 mil shares in early February and the earnings report is on 12th of February I believe.
biolase ist having also an UP
ticker?
remember don't sell this week under 3 dollars
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.